REGN - Company ID 0000872589
REGENERON PHARMACEUTICALS, INC. (REGN) reported revenue of $14.34B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $14.34B | +1.0% |
| FY 2024 | $14.20B | +8.3% |
| FY 2023 | $13.12B | +7.8% |
| FY 2022 | $12.17B | -24.3% |
| FY 2021 | $16.07B | +89.1% |
| FY 2020 | $8.50B | +29.6% |
| FY 2019 | $6.56B | +27.4% |
| FY 2018 | $5.15B | -12.4% |
| FY 2017 |
REGENERON PHARMACEUTICALS, INC. (REGN) reported revenue of $14.34B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, REGENERON PHARMACEUTICALS, INC.'s revenue grew from $445.82M to $14.34B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $5.87B |
| +20.8% |
| FY 2016 | $4.86B | +18.4% |
| FY 2015 | $4.10B | +45.5% |
| FY 2014 | $2.82B | +34.0% |
| FY 2013 | $2.10B | +52.7% |
| FY 2012 | $1.38B | +209.2% |
| FY 2011 | $445.82M | - |